“咳速停糖漿”可改善奧密克戎輕症上呼吸道症狀,貴州百靈一字漲停
格隆匯12月5日丨貴州百靈(002424.SZ)一字漲停,報9.09元,股價創今年4月以來新高,市值128億元。消息面上,12月2日晚間,由上海市公共衞生臨牀中心凌雲副院長為主要研究者完成的《咳速停糖漿治療新型冠狀病毒Omicron變異株感染輕症有效性和安全性的臨牀研究》成果論文,在國家級綜合醫學期刊《醫師在線》正式刊發,此次研究是與連花清瘟顆粒做的“頭對頭”試驗。論文顯示,貴州百靈“咳速停糖漿”治療奧密克戎變異株感染輕症可改善患者上呼吸道症狀,有利於新冠感染疾病痊癒,安全性良好,可以作為中藥治療新冠肺炎的選擇之一。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.